TAIPEI, Taiwan, Feb. 2 /Xinhua-PRNewswire/ -- OculusGen Biomedical Inc. (OBI) announced that it has 100% acquired Pro Top & Mediking, a Taiwan company that has successfully developed a latest invention -- A Collagen Matrix which significantly increased the success rate for glaucoma and other selective ophthalmic surgeries. This acquisition was made December 2005, detail amount was not disclosed.
The OculusGen(R) Collagen Matrix Implant, the product commercialized by Pro Top & Mediking, has been approved by four university hospitals in both Taiwan and China. The first IRB approval was made last June and afterward. Clinical trial has been conducted in these hospitals and the result is very encouraging.
OculusGen(R) is the only product of its type worldwide and its research team is formed by several ophthalmologists and biologists. OculusGen Biomedical Inc. is honored to have Dr. Robert Ritch as the chief consultant. OBI is actively participating in the ophthalmology congresses worldwide and recruiting distributors around the world, except some countries that has special regulation, such as USA.
For the coming World Ophthalmology Congress 2006 in Brazil, Pro Top & Mediking Company has a Symposium at WOC on February 21st and the topic is -- NOVEL BIOGRADEABLE IMPLANT LEADS THE WAY TO THE NEW GENERATION OF GLAUCOMA SURGERY -- ANTI SCARRING WITHOUT THE FIBROBLAST INHIBITION. This symposium will be chaired by Dr. Robert Ritch and Dr. Wesley Hsu, a former fellow to MIT and Harvard Medical School, will present the mechanism of the product and Dr. Henry Shen-Lih Chen, glaucoma specialist, will present the clinical findings from those trials. Furthermore, the Company is organizing a global training seminar that will be held in Taipei 31st March-1st April. For those who are interested in marketing this product should approach the company directly for further information.
OculusGen(R) is primarily designed to increase the success rate of glaucoma filtration surgery. To use OculusGen(R), simply implant OculusGen(R) on the top of the sclera flap under conjunctiva before the suturing. OculusGen is biodegraded within 90 days and it normalizes the bleb function by offering both physical and physiological effects. Good results were found in the animal and preliminary clinical trial without any anti-metabolite. Ophthalmologists simply operate with their own traditional techniques (trabeculectomy), requires no further training.
In addition, OculusGen(R) can be used in other selected ophthalmic surgeries, such as pterygium excision, eye plastic surgery, strabismus correction surgery, conjunctiva scar removal surgery, and nasolacrimal duct surgery, etc to prevent scar formation and speed up wound healing.
OculusGen(R) follows a strict quality management system and it is a biocompatible collagen implant. It is now processing an application for the CE Mark and expects to attain the mark in April 2006. US FDA IDE submission will be made in a month or two.
CONTACT: OculusGen Biomedical Inc. Michael, H.J. Lai, Tel: +886-2-2771-7098 Fax: +886-2-2721-8516 Email: mikelai@oculusgen.com Web: www.oculusgen.com
OculusGen Biomedical Inc.
CONTACT: Michael, H.J. Lai, of OculusGen Biomedical Inc.,+886-2-2771-7098, or fax, +886-2-2721-8516, or mikelai@oculusgen.com
Web site: http://www.oculusgen.com/
